Esophageal Cancer Clinical Trial Tracker — Monitor ESCC, EAC, and GEJ Research

Esophageal cancer trial activity in 2026

Esophageal cancer encompasses two biologically distinct diseases — esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) — that require separate monitoring strategies. With over 77 trials active on ClinicalTrials.gov and 38 currently recruiting, this is one of the most active GI oncology spaces in clinical development.

Critical signals to track:

• PD-1 + CTLA-4 dual checkpoint combinations in ESCC (following CheckMate 648, KEYNOTE-590 successors)
• HER2-targeted ADCs (T-DXd, RC48) in HER2-positive EAC and gastroesophageal junction cancers
• CLDN18.2-targeted therapies crossing over from gastric cancer into GEJ adenocarcinoma
• FGFR2b-targeted therapies in FGFR2b-amplified EAC
• Neoadjuvant and perioperative combination trials for resectable esophageal cancer
• Barrett's esophagus chemoprevention trials — a distinct, prevention-focused segment

What we monitor for esophageal cancer

Configure a search profile to capture the specific esophageal cancer subtype and trial stage you care about:

• Condition keywords: "esophageal cancer", "esophageal squamous cell carcinoma", "esophageal adenocarcinoma", "Barrett's esophagus", "gastroesophageal junction", "GEJ cancer"
• Phase filter: Phase 1 for early pipeline, Phase 2/3 for late-stage and registration-enabling studies
• Sponsor filter: Industry-sponsored for competitive intelligence, or all sponsors
• Status filter: Recruiting only, or all active studies including not yet recruiting

The esophageal cancer treatment landscape in 2026

Immunotherapy consolidation in ESCC

Esophageal squamous cell carcinoma — the dominant subtype globally and in Asia — has been transformed by PD-1 inhibitor approvals. The current generation of trials is testing dual checkpoint combinations, novel immune mechanisms (LAG-3, TIGIT), and immunotherapy plus radiotherapy in locally advanced disease. Companies with ESCC programs are monitoring competitor Phase 2/3 trial initiations closely, as this space is consolidating.

HER2-targeted opportunities in EAC and GEJ

HER2 overexpression occurs in approximately 20% of EAC and GEJ cancers. Following T-DXd's approvals in breast and gastric cancer, multiple programs are exploring HER2-targeted ADCs in esophageal adenocarcinoma. RC48-ADC, pertuzumab combinations, and novel bispecifics are all in active clinical evaluation, with several Phase 2/3 trials opened in 2025–2026.

CLDN18.2 — from gastric cancer into GEJ

Zolbetuximab's approval in CLDN18.2-positive gastric/GEJ cancer has made claudin 18.2 a validated target. Multiple bispecific antibodies and CAR-T programs targeting CLDN18.2 are now entering Phase 1 trials, with GEJ adenocarcinoma as a co-primary indication alongside gastric cancer. This is a fast-moving target to track.

Perioperative and neoadjuvant evolution

Following CheckMate 577 (nivolumab adjuvant post-neoadjuvant CRT), the field is moving toward perioperative immunotherapy. Phase 2/3 trials adding checkpoint inhibitors to FLOT or CROSS-based regimens are actively enrolling, with results expected to reshape the resectable disease paradigm.

Who uses esophageal cancer trial monitoring

GI oncology BD and competitive intelligence teams

Companies developing assets across the upper GI tract — gastric, GEJ, and esophageal cancers — monitor trial registrations as the earliest signal of competitor program advancement in each subtype.

Thoracic and GI surgical oncologists

Surgeons at academic medical centers monitor perioperative trial registrations to identify multimodal treatment studies relevant to their resectable esophageal cancer patients.

Gastroenterologists managing Barrett's esophagus

Barrett's esophagus surveillance programs generate a high-risk population potentially eligible for chemoprevention trials. Gastroenterologists tracking prevention trial registrations can connect eligible patients with studies before malignant progression.

Frequently asked questions

Can I track ESCC and EAC separately?

Yes. On the Starter plan ($49/month), you can create separate profiles — one with "esophageal squamous cell" keywords and one with "esophageal adenocarcinoma" or "Barrett's" keywords. Each profile generates its own daily digest.

Does this include trials that also enroll gastric cancer patients?

ClinicalTrials.gov lists all conditions a trial enrolls. Studies that include both gastric and esophageal/GEJ patients will appear if your keywords match any of the listed conditions.

How is this different from ClinicalTrials.gov alerts?

ClinicalTrials.gov email alerts lack phase filtering, sponsor type filtering, and organized digest formatting. DataLookout delivers filtered, labeled, digestible alerts for esophageal cancer specifically.